Introduction {#Sec1}
============

Esophageal cancer is the sixth and fourth cause of cancer-related mortality in the world and in China^[@CR1],[@CR2]^, with ESCC accounting for 90% of all diagnosed esophageal cancer cases^[@CR3]^. Although much progress has been achieved in the diagnosis and treatment, the prognosis of ESCC still remains unfavorable^[@CR4]--[@CR6]^. Currently, several factors are related to the outcome of ESCC including TNM stage and tumor differentiation. Nevertheless, even within the same staging category, there is disparate prognosis of ESCC because TNM stage could not reflect biological heterogeneity^[@CR7]^. Therefore, identification of new and accurate prognosis biomarkers in patients with ESCC is of great importance. A growing number of studies have suggested that platelets play a vital role in tumor development, progression and metastasis^[@CR8],[@CR9]^. Platelets take part in the different steps of angiogenesis including proliferation, migration, extracellular matrix degradation, and adhesion of endothelial cells^[@CR10]^. Activated platelets are involved at cancer-associated thrombosis by releasing inflammatory information, and interacting with neutrophils and monocytes. In addition to activated platelets, an elevated platelet count that has been found in cancer patients seem to be related to a higher proportion of cancer-related venous thromboembolism^[@CR11]^. Due to these mechanisms, platelets may serve as a potential therapeutic target^[@CR12]^. Some platelet indices including the platelet count (PLT), platelet distribution width (PDW), and platelet-lymphocyte ratio (PLR), can be readily available and have been confirmed to be associated with the prognosis of various cancers, such as non-small cell lung cancer, pancreatic adenocarcinoma, cervical cancer, and colon cancer^[@CR13]--[@CR17]^.

Recently, some researches have showed that an increased pretreatment PLT or PLR could serve as an independent prognosis factor in patients with ESCC^[@CR18],[@CR19]^. However, whether PDW is related to the prognosis in ESCC remains unknown. Therefore, the aim of this retrospective study was to evaluate the prognostic value of PDW in ESCC, and to investigate the relationship between PDW and the clinical-pathological features.

Results {#Sec2}
=======

Patient characteristics {#Sec3}
-----------------------

After screening, 495 patients (428 male and 67 female) with complete follow-up data were enrolled in the final study. The median age at diagnosis was 62 years (Interquartile range: 55--67 years). 38 (7.8%) with well differentiated pathology grade, 326 (67.1%) with middle differentiated pathology grade, 121 (24.9%) with poorly differentiated pathology grade, and 1 (0.02%) with undifferentiated pathology grade. In addition, 223 (45.1%) had high- pathological stage (≥TNM3a-3c), 181 (36.6%) had middle- pathological stage (=TNM2a-2b), 91 (18.4%) early- pathological stage (=TNM1a-1b). 264 (53.3%) had lymph node invasion, 138 (27.9%) had vessel invasive, 169 (34.1%) had nerve infiltration, and 339 (68.5%) only received surgery. The median of hospital time after operation was 11(Interquartile range: 10--13), and the median of the PDW was 13.2(Interquartile range: 11.7--15.0). The clinical-pathological features are listed in Table [1](#Tab1){ref-type="table"}.Table 1Difference in PDW ratio according to clinical characteristics in ESCC patients.VariablesCasesN%SexMale42886.5Female6713.5Age at therapy initiation(years)Median62Interquartile range(55--67)Pathology gradeWell differentiated387.8middle differentiated32667.1Poorly differentiated12124.9Undifferentiated10.02Depth of tumorT1a--1b5110.3T210020.2T334469.5Lymph node metastasisN023146.7N116533.3N27414.9N3255.1Pathological stage1a--1b9118.42a--2b18136.63a--3c22345.1Vessel invasiveYes13827.9No35772.1Nerve infiltrationYes16934.1No32665.9Treatment regimenS33968.5S plus postoperative C11122.4S plus postoperative CRT459.1Hospital time after operation(days)Median11Interquartile range(10--13)PDWMedian13.2Interquartile range(11.7--15.0)PlateletMedian198.5Interquartile range(160.0--236.0)AlbuminMedian42.1Interquartile range(39.5--44.2)RDWMedian12.8Interquartile range(12.3--13.3)Aspartate transaminaseMedian22Interquartile range(19.0--27.0)FibrinogenMedian3.73Interquartile range3.19--4.34HemoglobinMedian13.7Interquartile range(12.7--14.6)Abbreviations: S, surgery; C, chemotherapy; CRT, chemoradiotherapy; PDW, platelet distribution width; RDW, red cell distribution width.

High PDW is a predictor of adverse pathological features {#Sec4}
--------------------------------------------------------

The areas under the ROC curves (AUCs) were 0.716 and 0.615 for OS and DFS, respectively (Fig. [1](#Fig1){ref-type="fig"}). The larger AUC of 0.716 acquired for OS was chose to be the optimal cut-off value of 13.4, with maximum specificity (81.0%) and sensitivity (59.49%) (Fig. [1A](#Fig1){ref-type="fig"}). According to the cut-off of PDW, 254 patients (51.3%) with PDW \< 13.4 were grouped into the low PDW group, whereas the remaining 241 patients (48.7%) with PDW ≥ 13.4 were divided into the high PDW group. The association between PDW and clinical-pathological features are shown in Table [2](#Tab2){ref-type="table"}. None of the clinical-pathological features was notably related to the PDW including gender, age at diagnosis, pathology grade, lymph node metastasis, pathological stage, vessel invasive, treatment regimen, albumin, fibrinogen, and hemoglobin. However, an elevated PDW was significantly associated with depth of tumor (P = 0.031), nerve infiltration (P = 0.016), hospital time after operation (P = 0.020), platelet (P \< 0.001), red cell distribution width (P \< 0.001), and aspartate transaminase (P = 0.001). Moreover, high PDW independently predicted depth of tumor (OR = 1.575, P = 0.040), lymph node metastasis (OR = 1.704, P = 0.009), pathological stage (OR = 0.464, P = 0.007), and nerve infiltration (OR = 1.527, P = 0.042) using logistic regression analysis (Table [3](#Tab3){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}).Figure 1ROC curves analysis of PDW for survival outcomes in patients with ESCC. (**A**) OS revealed the largest AUC (0.716), while PDW cutoff was set at 13.4 for the largest Youden Index (0.405) obtained (sensitivity, 81.0%; specificity, 59.5%). (**B**) DFS revealed the AUC (0.615). OS: overall survival; DFS: disease free survival; PDW: platelet distribution width; AUC: area under the ROC curve; ESCC: esophageal squamous cell carcinoma.Table 2Relationship between preoperative PDW and clinical-pathological features in patients with ESCC.CharacteristicsTotal patientsPDW \<13.4 (n = 254)PDW ≥13.4 (n = 241)*P* valueSexMale2192090.870Female3532Age at therapy initiation(years)≤601121170.321\>60142124Pathology gradeWell differentiated22160.390middle differentiated170156Poorly differentiated5665Undifferentiated01Depth of tumorT1a--1b3417**0.031**T24456T3176168Lymph node metastasisN01231080.260N18976N23242N31015Pathological stage1a--1b49420.8442a--2b93883a--3c112111Vessel invasiveYes63750.117No191166Nerve infiltrationYes7495**0.016**No180146Treatment regimenS1631760.102S plus postoperative C6447S plus postoperative CRT2718Hospital time after operation(days)≤14215184**0.020**\>143957PlateletMedian222.0171.0**\<0.001**Interquartile range(190.0--257.0)(142.0--206.0)AlbuminMedian42.141.90.992Interquartile range(39.7--44.1)(39.3--44.4)RDWMedian12.712.9**\<0.001**Interquartile range(12.3--13.2)(12.4--13.4)Aspartate transaminaseMedian21.023.0**0.001**Interquartile range(19.0--26.0)(19.0--29.0)FibrinogenMedian3.83.7**0.108**Interquartile range(3.3--4.4)(3.1--4.3)HemoglobinMedian13.813.70.169Interquartile range(12.8--14.7)(12.6--14.5)Abbreviations: S, surgery; C, chemotherapy; CRT, chemoradiotherapy; PDW, platelet distribution width; RDW, red cell distribution width.Table 3Logistic regression analysis of PDW and its predictive value for adverse pathological outcomes.Adverse pathological outcomesAdjusted OR95% CIP valuePathology grade1.2090.860--1.70.275Depth of tumor1.5751.022--2.428**0.040**Lymph node metastasis1.7041.144--2.537**0.009**Pathological stage0.4640.264--0.814**0.007**Vessel invasive1.2240.791--1.8960.364Nerve infiltration1.5271.015--2.297**0.042**Figure 2Forest map showing logistic regression analysis of PDW and its predictive value for adverse pathological outcomes.

High PDW is related to poor OS and DFS {#Sec5}
--------------------------------------

The Kaplan--Meier curves exhibited that patients with high PDW had a worse OS (P \< 0.001, Fig. [3A](#Fig3){ref-type="fig"}) compared with low PDW group. In subgroup analysis according to lymph node metastasis and pathological stage, high PDW was related to worse OS for patients with or without lymph node metastasis (both P \< 0.001) and less or more advanced stage (both P \< 0.001) (Figs [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}). In addition, univariate analysis shown that high PDW was correlated with worse OS (HR = 5.111, P \< 0.001) (Table [4](#Tab4){ref-type="table"}). Using multivariate analysis, high PDW (HR = 1.194, P \< 0.001), lymph node metastasis (P \< 0.05), nerve infiltration (P = 0.004), and hospital time (P = 0.009) were notable related to worse OS (Table [4](#Tab4){ref-type="table"}).Figure 3Kaplan--Meier curves for OS (**A**) and DFS (**B**) which was stratified according to PDW value (PDW \<13.4 vs. PDW ≥13.4) for ESCC patients after surgery. The difference was evaluated by log-rank tests.Figure 4Subgroup analysis based on lymph node metastasis, Kaplan--Meier curves for OS (**A**,**B**) and DFS (**C,D**), which was stratified according to PDW value (PDW \<13.4 vs. PDW ≥13.4) for ESCC patients after surgery. The difference was evaluated by log-rank tests.Figure 5Subgroup analysis based on pathological stage, Kaplan--Meier curves for OS (**A,B**) and DFS (**C,D**), which was stratified according to PDW value (PDW \<13.4 vs. PDW ≥13.4) for ESCC patients after surgery. The difference was evaluated by log-rank tests.Table 4Overall survival analyses according to preoperative PDW in 495 patients with ESCC.VariablesUnivariateMultivariateHR95% CI*P* valueHR95% CI*P* valuePDW (≥13.4 vs. \<13.4)5.1113.101--8.425**\<0.001**1.1941.120--1.273**\<0.001**Sex (male vs.female)1.6760.845--3.3260.139Age (\>60 vs. ≤60)1.2380.833--1.8380.291**Depth of tumor**T1a--1b0.2960.093--0.937**0.038**0.4470.116--1.7220.242T20.6070.355--1.0380.6070.4350.135--1.3990.162T31.0001.000**Lymph node metastasis**N00.1120.056--0.222**\<0.001**0.0730.015--0.363**0.001**N10.3080.164--0.576**\<0.001**0.3310.168--0.650**0.001**N20.4320.219--0.855**0.016**0.4860.240--0.985**0.045**N31.0001.000**Pathological stage**1a--1b0.1940.084--0.447**\<0.001**2.3840.184--30.7990.5062a--2b0.3950.251--0.623**\<0.001**1.5560.386--6.2830.5343a--3c1.0001.000Vessel invasive (absence vs. presence)1.7931.197--2.686**0.005**1.0980.704--1.7130.681Nerve infiltration (absence vs. presence)1.9901.343--2.948**0.001**1.8551.214--2.836**0.004Treatment regimen**S1.4250.656--3.0990.371S plus postoperative C1.4300.611--3.3480.410S plus postoperative CRT1.000Hospital time (days) (\>14 vs. ≤14)1.8111.169--2.803**0.008**1.8281.159--2.881**0.009**Platelet0.9960.992--0.999**0.018**1.0000.996--1.0040.904Albumin0.9310.884--0.981**0.007**0.9470.892--1.0060.076RDW1.2581.016--1.557**0.035**1.0720.838--1.3700.579Aspartate transaminase0.9950.972--1.0190.709Fibrinogen1.1370.909--1.4220.262Hemoglobin0.8310.729--0.948**0.006**0.8530.726--1.0020.053Abbreviations: S, surgery; C, chemotherapy; CRT, chemoradiotherapy; PDW, platelet distribution width; RDW, red cell distribution width.

By Kaplan--Meier analysis, the DFS was poor in the high PDW group (P \< 0.001, Fig. [3B](#Fig3){ref-type="fig"}). Similarly, based on subgroup analysis, with lymph node metastasis (P \< 0.001) and advanced stage (P \< 0.001) could serve as predictors for short DFS in patients with ESCC, which was not observed in patients without lymph node metastasis (P = 0.291) and less advanced stage (P = 0.219) (Figs [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}). In the univariate analysis, high PDW was a significant predictor of unfavorable DFS (HR = 2.302, P \< 0.001) (Table [5](#Tab5){ref-type="table"}). After adjustment for confounders, high PDW (HR = 2.562, P \< 0.001), lymph node metastasis (P \< 0.05), and surgery (P = 0.047) were correlated with decreased DFS (Table [5](#Tab5){ref-type="table"}). In a word, PDW was an independent prognostic factor for patients with ESCC undergoing surgery.Table 5Disease-free survival analyses according to preoperative PDW in 495 patients with ESCC.VariablesUnivariateMultivariateHR95% CI*P* valueHR95% CI*P* valuePDW (≥13.4 vs. \<13.4)2.3021.567--3.383**\<0.001**2.5621.733--3.786**\<0.001**Sex (male vs.female)1.5450.830--2.8780.170Age (\>60 vs. ≤60)0.8810.610--1.2730.501**Depth of tumor**T1a--1b0.8380.435--1.6140.597T20.6010.357--1.0110.055T31.000**Lymph node metastasis**N00.1600.084--0.303**\<0.001**0.2050.074--0.569**0.002**N10.2660.141--0.500**\<0.001**0.2650.136--0.515**\<0.001**N20.4710.243--0.915**0.026**0.4240.217--0.827**0.012**N31.0001.000**Pathological stage**1a--1b0.3760.203--0.694**0.002**1.0390.363--2.9750.9432a--2b0.5110.337--0.775**0.002**1.0820.517--2.2610.8353a--3c1.0001.000Vessel invasive (absence vs. presence)1.3760.927--2.0430.114Nerve infiltration (absence vs. presence)1.6401.131--2.380**0.009**1.4240.960--2.1130.079**Treatment regimen**S0.4960.280--0.878**0.016**0.5510.306--0.993**0.047**S plus postoperative C1.3440.748--2.4160.3231.3040.719--2.3640.382S plus postoperative CRT1.000Hospital time (days) (\>14 vs. ≤14)1.2140.773--1.9050.399Platelet0.9980.995--1.0010.285Albumin0.9690.922--1.0190.217RDW1.1490.931--1.4180.195Aspartate transaminase0.9970.975--1.0190.791Fibrinogen0.9310.748--1.1590.524Hemoglobin0.9620.847--1.0910.545Abbreviations: S, surgery; C, chemotherapy; CRT, chemoradiotherapy; PDW, platelet distribution width; RDW, red cell distribution width.

Discussion {#Sec6}
==========

Numerous researches showed that platelet activation play an important part in cancer progression. Thrombocytosis is related to worse clinical outcome in patients with various cancers, including ovarian cancer, colorectal cancer, and pancreatic cancer^[@CR20]--[@CR22]^. The PDW that is one of the platelet indices not merely check platelet volume heterogeneity, but also reactive platelet activity. Recently, several studies revealed that a high PDW is an unfavorable prognosis factor in melanoma patients, laryngeal cancer, and gastric cancer^[@CR23]--[@CR25]^. To the best of our knowledge, the prognostic value of the preoperative PDW in ESCC patients remains unknown.

This was the first retrospective research revealed that a PDW with a cut-off 13.4 fL was an independent prognostic factor for the OS and DFS in ESCC patients. Our findings reported that an elevated PDW was correlated with depth of tumor, nerve infiltration, and hospital time after operation. Moreover, high PDW was an independent predictor for ESCC patients with lymph node metastasis according to further subgroup analyses.

Nevertheless, the potential mechanism by which PDW have an effect on cancer progression is unclear. One possible cause is that platelets facilitate the hypercoagulability in tumor. Activated platelets produce a procoagulant micro-environment and aggregate with tumor cell. Platelet-derived growth factor (PDGF) family members including PDGF-A, PDGF-B, PDGF-C and PDGF-D, play a vital role in cancer cell proliferation, apoptosis, transformation, invasion, metastasis and angiogenesis^[@CR26]--[@CR31]^. In esophageal cancer, PDGF-D expression is associated with clinical-pathological features and worse survival. Moreover, platelet-derived growth factor-D contributes to proliferation and invasion of esophageal squamous cell carcinoma by up-regulating NF-κB signaling pathways^[@CR32]^. Consistent with previous studies, our findings indirectly suggested anti-platelet could serve as one part of cancer adjuvant therapy^[@CR33]^.

Another possible mechanism is that bone marrow cells malfunction may be associated with the lower PDW. PDW reflects platelet heterogeneity, which is caused by heterogeneous demarcation of megakaryocytes^[@CR34]^. Cytokines, including interleukin-6 (IL-6), macrophage colony stimulating factor (M-CSF), and granulocytes colony stimulating factor (G-CSF), have an effect on megakaryocytic maturation, platelet production, and platelet size^[@CR35]^. IL-6 facilitates cancer cell proliferation, invasion, and metastasis. IL-6 is correlated with the prognosis and depression of cancer patients and is considered to the therapy target^[@CR36]--[@CR38]^. Moreover, G-CSF stimulates megakaryopoiesis and constrains tumor to proliferation. M-CSF was an important factor in the cancer microenvironment, involving in the interactions between tumor-infiltrated macrophages and tumor cells^[@CR39]--[@CR41]^. Those reports are in accord with the point that activated platelets participate in the pathogenesis of esophageal cancer.

There were several limitations of our study: first, this was the single-center design and retrospective study, which might have selection bias. Second, the biological mechanism of PDW affecting prognosis need to explored. Third, a controversial cut-off value determined by different ways, such as mean, ROC curve, and C index, could be the optimal predictor of clinical outcome in ESCC patients. In this study, we chose ROC curve to determine the cut-off value. Future studies with multi-center design and prospective trials are necessary to validate the prognostic value of PDW in ESCC patients.

An elevated preoperative PDW indicates a worse OS and DFS of patients with newly diagnosed ESCC undergoing surgery. Our finding may contribute to assess the prognosis of ESCC.

Methods {#Sec7}
=======

Patient recruitment and data collection {#Sec8}
---------------------------------------

This retrospective study was approved by the Ethics Committee of Zhejiang Cancer Hospital, and included 590 ESCC patients who were newly diagnosed between 2008 and 2013. 95 patients who met the following standard were excluded from the study: neoadjuvant chemotherapy or radiotherapy before surgery; loss to follow-up; data missing; concomitant disease that could interfere with platelet, including autoimmune disease, splenic disease, severe hypertension, and a history of blood transfusion; other factors that could affect the PDW, including megaloblastic anemia, acute myeloid leukemia, splenectomy, giant platelet syndrome, and thrombotic disease. The enrolled 495 patients completed written informed consent.

The pretreatment peripheral blood cell count was checked via a SYSMEX XE-2100 (Sysmex, Kobe, Japan) Automatic Blood Cell Analyzer. The PDW measurement is the first time of admission.

Follow-up strategy {#Sec9}
------------------

After surgery, patients were followed up every three months for the first year, six months during the second year and 12 months thereafter. Physical examination, blood routine examination, and medical history were achieved conventionally. Bone scans, chest/abdominal CT/MRI, and chest radiography were acquired when in cases of suspicious metastasis or recurrence.

Statistical analysis {#Sec10}
--------------------

The PDW was analyzed as continuous variables and the clinical-pathological features were counted as categorical variables. The optimal cut-off value of PDW for predicting survival was determined by the ROC curve analysis. The relationship between PDW and clinical-pathological features in ESCC was analyzed by chi-square tests. The Kaplan-Meier method and the log-rank test were used for the overall survival (OS) and disease-free survival (DFS) analyses. The association between PDW and clinical-pathological features were investigated by logistic regression analysis. Clinical-pathological features with P \< 0.01 were selected to be the subgroup factor. Subgroup analysis was based on lymph node metastasis and pathological stage. Whether the OS and DFS was an independent prognosis factor was determined by Cox proportional hazards regression models. Risk factors with P \< 0.01 in univariate analysis were chosen to multivariate analyses. The SPSS software version 19.0 (IBM SPSS, Chicago, IL, USA) was utilized for statistical analysis.
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------------------------------------------
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